Recently, Tsai et al. indicated that the combination of an EGFR-TKI and bevacizumab not only improves PFS but also improves OS in patients with advanced-stage EGFR-mutant NSCLC harboring the L858R mutation [21]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.